Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Newstrike Brands Ltd NWKRF

Healthcare Biotechnology Cannabis
"Newstrike Brands Ltd is a licensed producer and cultivator of medical cannabis based in Brantford, Ontario. The company cultivates and sells both forms including dried and fresh marihuana."


OTCPK:NWKRF - Post by User

Newstrike Brands Ltd > This is risky at .57 like it or not
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Extallioneson Nov 20, 2017 8:11pm
225 Views
Post# 27000261

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:This is risky at .57 like it or not

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:This is risky at .57 like it or notI am only summarizing what I believed to be Quantum's position from his various posts.  He appears to have agreed that that is his assessment of the situation.  I generally agree with him, but believe CMED will be valued higher than $15.00 if the deal with HIP completes, given the acquisition (despite the increase in the market cap).  

I would love to see the deal go through.  I don't know if it will or not, and I agree that 38% lock-up could be a huge roadblock, but either way, with a sales licence "imminent", I'm not too worried about HIP's share price.  I also believe that if it does go through, CMED will be a great company to be invested in in the long run, regardless of its current valuation ($15 or higher).  I'm also averaged in at around .34-.35, so I see upside no matter which way it goes.    
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities